Dermapharm acquires Medical Devices Business Unit from Riemser

Grünwald/Berlin, September 21, 2017. Dermapharm and Riemser announce that both parties have signed an agreement on the acquisition of Riemser’s Hyperthermic Medical Devices Business by Dermapharm. The parties have agreed not to disclose any details of the transaction.


The Medical Devices Business consists of an innovative OTC medical applications portfolio selectively targeting mosquito and insect stitches (bite away), herpes blisters (Herpotherm).


Under Riemser’s ownership the business experienced significant growth while Riemser’s primarily strategic focus is on prescription-based specialty pharmaceutical products; thus, the Hyperthermic Medical Devices Business with its OTC positioning was considered non-core. Dermapharm, with its very strong access to dermatologists and OTC distribution capabilities, is the ideal next owner of the Medical Devices Business as it is very well positioned to promote and expand the market presence in Germany as well as internationally.


"As one of the leading companies within the OTC-dermatology market environment we are really pleased and happy to further strengthen our end-consumer product portfolio through the Medical Devices Business" said Stefan Grieving, board member in charge for Marketing and Sales of Dermapharm. "The highly innovative medical products bite away and Herpotherm provide significant and attractive access opportunities to new customer groups within the OTC-market environment".


Konstantin von Alvensleben, Chairman of the Management of Riemser Pharma GmbH, comments on the acquisition as follows: "The Medical Devices Business already illustrated tremendous potential under Riemser ownership. Dermapharm is the logical owner of this business and we look forward seeing them develop the business even further."


FERBER & Co., the Munich-based M&A boutique, acted as the financial advisor to Riemser on this transaction.

About Dermapharm AG

Established in 1991, Dermapharm is a mid-sized, family-owned company which is specialized in the production and marketing of high-grade dermatology and allergology pharmaceuticals. Dermapharm is a strong and reliable partner for patients, doctors, practitioners as well as pharmacists.


Over the past years Dermapharm managed to incorporate additional medium-sized companies to its core company group which obtains a prime market position within the gynecology, corticoids as well as vitamins market segments. The continuous development is based on a broad product portfolio including prescription-free and prescription-based pharmaceuticals, nutrition supplements, medical products and cosmetics.


Dermapharm´s modern production site is based in Brehna near Leipzig where the company develops and produces its pharmaceuticals for the entire group. With this strategy Dermapharm is committed to Germany as a production location.


About Riemser Pharma GmbH

Established in December 1992, the company is an expert regarding therapeutics for specialty medicines with high medical need.


The company offers a proprietary product portfolio, which covers different therapeutic fields ranging from oncology and neuroscience to infectious diseases and dermatology. It purchases, licenses, markets and distributes pharmaceutical products. Over 300 approvals worldwide, of which 30 took place in the last two years, are a testament with respect to the company's profound knowledge of the market.


By making strategic acquisitions in Europe, Riemser continues to further increase its expertise and competence in its core markets. The company has been growing sustainably for years based on its focus on non-cyclical segments in the pharmaceutical market. Not only due to this strategy Riemser is the perfect partner for international companies who seek to access the European Market with their pharmaceutical products.


Riemser is situated in Germany (Greifswald-Insel Riems as Headquarter, Berlin and Greifswald as business sites), has a German subsidiary in Schiffweiler as well as additional subsidiaries located in France (Paris) and the UK (London- Maidenhead). In 2012, Riemser was acquired by the independent private investment company Ardian.

Press contact:

Press Office
RIEMSER Pharma GmbH
Email: pressestelle@RIEMSER.com
www.RIEMSER.com